COVID-19 risk factor benign prostatic hyperplasia systematic review

膀胱浸润性尿路上皮癌 PD-L1(SP263) 病理 共识

膀胱浸润性尿路上皮癌 PD-L1(SP263) 病理 共识

Bladder Invasive Urothelial Carcinoma PD-L1 (SP263) Immunohistochemical Detection Consensus

经尿道前列腺电切术 1470nm激光汽化术 良性前列腺增生 Meta分析 系统评价 随机对照试验 非随机对照试验

5-alpha Reductase Inhibitors/*administration & dosage Adrenergic alpha-1 Receptor Antagonists/*administration & dosage Drug Therapy Combination Dutasteride/*administration & dosage Erectile Dysfunction/chemically induced/diagnosis Humans Male Prostatic Hyperplasia/diagnosis/*drug therapy/epidemiology Randomized Controlled Trials as Topic/methods Tamsulosin/*administration & dosage Treatment Outcome Benign prostatic hyperplasia Dutasteride Meta-analysis Randomized controlled trials Tamsulosin published studies thus no ethical approval and patient consent are required. CONSENT FOR PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Adrenergic alpha-1 Receptor Antagonists/*administration & dosage Adrenergic beta-3 Receptor Agonists/administration & dosage Cholinergic Antagonists/administration & dosage Drug Therapy Combination Humans Lower Urinary Tract Symptoms/*drug therapy Male Phosphodiesterase 5 Inhibitors/*administration & dosage Prostatic Hyperplasia/complications Quality of Life Randomized Controlled Trials as Topic 5-alpha reductase inhibitor Lower urinary tract symptoms alpha blockers anticholinergic: systematic review benign prostatic hyperplasia randomized trials

Adrenergic alpha-1 Receptor Antagonists Aged Humans Indoles Lower Urinary Tract Symptoms Male Naphthalenes Piperazines Prostatic Hyperplasia Quinazolines Randomized Controlled Trials as Topic Urological Agents

Greenlight high-performance system 120-W laser vaporization transurethral resection of the prostate benign prostatic hyperplasia meta-analysis

Adrenergic alpha-1 Receptor Antagonists/*administration & dosage Adrenergic alpha-Antagonists Dose-Response Relationship Drug Humans Male Middle Aged Prostatic Hyperplasia *Quality of Life Sulfonamides/*administration & dosage Tamsulosin Prostatic hyperplasia alpha blockers

Male Humans *Papillomavirus Infections/complications/epidemiology/prevention & control Human Papillomavirus Viruses Mendelian Randomization Analysis Papillomaviridae/genetics Human papillomavirus 18 *Urinary Bladder Neoplasms/epidemiology/complications HPV prevalence bladder cancer human papillomavirus mendelian randomization meta-analysis

膀胱癌 MALAT1 Meta分析

Adjuvants Immunologic Administration Intravesical BCG Vaccine/therapeutic use Bayes Theorem *Covid-19 Duration of Therapy Humans *Mycobacterium bovis Neoplasm Invasiveness Neoplasm Recurrence Local/drug therapy Network Meta-Analysis Pandemics *Urinary Bladder Neoplasms/drug therapy *Urology

Humans Female Male *Urinary Bladder Neoplasms/etiology/microbiology RNA Ribosomal 16S/genetics Urinary Bladder/microbiology *Microbiota/genetics Bacteria/genetics Bladder cancer Gender Urinary microbiota Uropathogens of interest.

Cohort Studies Diet Female Humans Male Prospective Studies Risk Factors Thiamine *Urinary Bladder Neoplasms/epidemiology/etiology/prevention & control Vitamin A Vitamin B 12 *Vitamin B Complex B group vitamins Bladder cancer Nutritional oncology Pooled cohort analysis

*Carcinoma Transitional Cell/drug therapy Female Humans Immune Checkpoint Inhibitors/therapeutic use Immunotherapy *Lung Neoplasms/pathology Male Platinum/therapeutic use Programmed Cell Death 1 Receptor *Urinary Bladder Neoplasms/drug therapy

Apoptosis B7-H1 Antigen/genetics/metabolism *Carcinoma Transitional Cell/pathology Cystectomy Humans Immune Checkpoint Inhibitors Ligands Lymph Node Excision Neoplasm Recurrence Local/pathology Prognosis Programmed Cell Death 1 Receptor Urinary Bladder *Urinary Bladder Neoplasms/pathology bladder urothelial carcinoma meta-analysis prognostic value programmed cell death ligand-1 radical cystectomy commercial or financial relationships that could be construed as a potential conflict of interest.

Radical cystectomy bladder preservation distant metastasis rate (DMR) muscular invasive bladder cancer (MIBC) survival rate form (available at https://dx.doi.org/10.21037/tau-21-564). The authors have no conflicts of interest to declare.

Antineoplastic Combined Chemotherapy Protocols/adverse effects Bayes Theorem *Carcinoma Transitional Cell/drug therapy/surgery Humans Network Meta-Analysis *Urinary Bladder Neoplasms/drug therapy/surgery Ici Pd-1 Pd-l1 adjuvant therapy chemotherapy urothelial carcinoma

Adult Aged Aged 80 and over Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use B7-H1 Antigen/antagonists & inhibitors Carcinoma/*drug therapy/immunology/mortality/pathology Clinical Decision-Making Female Humans Immune Checkpoint Inhibitors/adverse effects/*therapeutic use Male Middle Aged Patient Selection Progression-Free Survival Time Factors Urinary Bladder Neoplasms/*drug therapy/immunology/mortality/pathology Urothelium/*drug effects/immunology/pathology Immune-checkpoint inhibitor Meta-analysis Programmed death-ligand 1 Urothelial carcinoma interests/personal relationships which may be considered as potential competing interests: The authors certify that all conflicts of interest including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the article are listed as follows: Shahrokh Shariat owns or co-owns the following patents: methods to determine prognosis after therapy for prostate cancer. Granted 2002-09-06. Methods to determine prognosis after therapy for bladder cancer. Granted 2003-06-19. Prognostic methods for patients with prostatic disease. Granted 2004-08-05. Soluble Fas: urinary marker for the detection of bladder transitional cell carcinoma. Granted 2010-07-20. He has a consulting or advisory role for the following: Astellas Astra Zeneca Bayer BMS Cepheid Ferring Ipsen Jansen Lilly MSD Olympus Pfizer Pierre Fabre Roche Sanochemia Sanofi Takeda Urogen and Wolff. All remaining authors have declared no conflicts of interest.